Ligand Pharmaceuticals (LGND) said Tuesday it expects 2025 core adjusted earnings of $6.00 to $6.25 per diluted share.
Analysts polled by FactSet expect $6.03.
The company said revenue for the year is expected to be between $180 million and $200 million.
Analysts surveyed by FactSet expect $183.1 million.
For 2024, the company said it continues to expect core adjusted earnings of between $5.50 and $5.70 on revenue of $160 million to $165 million. Analysts polled by FactSet expect core adjusted earnings of $5.65 on revenue of $163.4 million.
Price: 115.08, Change: -1.27, Percent Change: -1.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。